Last reviewed 2026-05-27 · How we verify

V0057 - A mg

Pierre Fabre Dermatology · Phase 1 active Small molecule ✓ Verified May 2026

V0057 - A mg is a Small molecule drug developed by Pierre Fabre Dermatology. It is currently in Phase 1 development.

V0057 - A mg is a small molecule medication, also known as MG-S-2525, that has been studied in a bioequivalence trial comparing it to a reference formulation in healthy male subjects. The study, identified as NCT01861626, was conducted by Pierre Fabre Dermatology to evaluate the bioequivalence of V0057 - A mg and a reference formulation after single administration.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	V0057 - A mg
Sponsor	Pierre Fabre Dermatology
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Bioequivalence Study of V0057 Versus a Reference Formulation After Single Administration in Healthy Male Subjects (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

V0057 - A mg CI brief — competitive landscape report
V0057 - A mg updates RSS · CI watch RSS
Pierre Fabre Dermatology portfolio CI

Frequently asked questions about V0057 - A mg

What is V0057 - A mg?

V0057 - A mg is a Small molecule drug developed by Pierre Fabre Dermatology.

Who makes V0057 - A mg?

V0057 - A mg is developed by Pierre Fabre Dermatology (see full Pierre Fabre Dermatology pipeline at /company/pierre-fabre-dermatology).

What development phase is V0057 - A mg in?

V0057 - A mg is in Phase 1.

Manufacturer: Pierre Fabre Dermatology — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing